In the phase II LURET trial, 17 RET-rearranged NSCLC were treated with vandetanib, a multitargeted TKI, with 53% RR and a relatively short, if compared with other genomic-driven treatment in NSCLC, median PFS of 4.7 [69]. Here, RET is linked to non-small cell lung carcinoma.